The publication of two SURPASS-3 substudies in The Lancet Diabetes & Endocrinology reveals significant benefits of tirzepatide on liver and abdominal fat in people with type 2 diabetes, as well as on time in target glucose range.
The gain or loss of more than 5% bodyweight within a 2-year period is associated with an increased risk for major adverse cardiovascular events in people with type 2 diabetes, say researchers.